EAACI Biologicals Guidelines-Recommendations for severe asthma
Top Cited Papers
- 1 January 2021
- Vol. 76 (1), 14-44
- https://doi.org/10.1111/all.14425
Abstract
Severe asthma imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co-morbidities, complexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of severe asthma, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarification. These include selection of a certain biological (as they all target overlapping disease phenotypes), the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness. The EAACI Guidelines on the use of biologicals in severe asthma follow the GRADE approach in formulating recommendations for each biological and each outcome. In addition, a management algorithm for the use of biologicals in the clinic is proposed, together with future approaches and research priorities.This publication has 201 references indexed in Scilit:
- IL-33 promotes airway remodeling in pediatric patients with severe steroid-resistant asthmaJournal of Allergy and Clinical Immunology, 2013
- Effects of Omalizumab in Non-Atopic Asthma: Results from a Spanish Multicenter RegistryJournal of Asthma, 2013
- Pediatric severe asthma is characterized by eosinophilia and remodeling without TH2 cytokinesJournal of Allergy and Clinical Immunology, 2012
- Development and validation of the Composite Asthma Severity Index—an outcome measure for use in children and adolescentsJournal of Allergy and Clinical Immunology, 2012
- An essential role for TH2-type responses in limiting acute tissue damage during experimental helminth infectionNature Medicine, 2012
- A Complement–IL-4 Regulatory Circuit Controls Liver RegenerationThe Journal of Immunology, 2012
- GRADE guidelines: 9. Rating up the quality of evidenceJournal of Clinical Epidemiology, 2011
- Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City ChildrenThe New England Journal of Medicine, 2011
- Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research ProgramAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Omalizumab is effective in the long-term control of severe allergic asthmaAnnals of Allergy, Asthma & Immunology, 2003